Global InformationRezafungin information
 | |
| Clinical data | |
|---|---|
| Trade names | Rezzayo |
| Other names | Biafungin; CD101 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623021 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antifungal |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Excretion | Feces |
| Identifiers | |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| Chemical and physical data | |
| Formula | C63H85N8O17+ |
| Molar mass | 1226.412 g·mol−1 |
Rezafungin, sold under the brand name Rezzayo, is a medication used for the treatment of invasive candidiasis.[2] It is an echinocandin antifungal.[1][4]
Rezafungin was approved for medical use in the United States in March 2023,[1][5][6] and in the European Union in December 2023.[2][3]
- ^ a b c "Rezzayo- rezafungin injection, powder, lyophilized, for solution". DailyMed. 8 June 2023. Retrieved 26 December 2023.
- ^ a b c Cite error: The named reference
Rezzayo EPARwas invoked but never defined (see the help page). - ^ a b "Rezzayo Product information". Union Register of medicinal products. 22 December 2023. Retrieved 26 December 2023.
- ^ Zhao Y, Perlin DS (September 2020). "Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data". Journal of Fungi. 6 (4): 192. doi:10.3390/jof6040192. PMC 7712954. PMID 32998224.
- ^ "Rezzayo approved by FDA amid rapid Candida auris spread". thepharmaletter.com. 23 March 2023.
- ^ Syed YY (June 2023). "Rezafungin: First Approval". Drugs. 83 (9): 833–840. doi:10.1007/s40265-023-01891-8. PMID 37212966. S2CID 258831091.